Methylone, 2C-B, and MBDB Dosing for Lower Interaction Risk

The patent modifies the chemical structure of psychoactive compounds by changing parameters such as substituting aromatic rings with non-aromatic cyclic structures, altering side chain lengths, and modifying functional groups. These parameter changes result in new compounds (e.g., compounds of Formula I, II, III, IV) that maintain therapeutic efficacy while reducing harmful effects like serotonin syndrome and drug-drug interactions, thereby resolving the contradiction between efficacy and safety.

The patent develops shorter-acting psychoactive compounds with reduced half-lives compared to traditional MDMA and psilocybin. These short-acting compounds provide sufficient therapeutic effect during the treatment window but clear from the system faster, reducing cumulative toxicity and interaction risks. The temporary nature of these compounds allows for safer administration profiles while maintaining treatment effectiveness.

The patent creates psychoactive compounds with pharmacological profiles that enable safer self-administration. The reduced potency and shorter duration of action of these compounds allow patients to manage their own treatment without intensive provider monitoring. The compounds can be administered at lower doses with fewer severe adverse effects, empowering patients to take control of their treatment while maintaining safety through self-monitoring of symptoms.

The patent employs lower doses of psychoactive compounds that provide partial therapeutic effects rather than requiring high doses for full efficacy. This partial action approach reduces the intensity of provider monitoring needed while still achieving meaningful clinical improvement. The lower dose regime minimizes severe side effects and allows for more flexible administration settings, improving accessibility.

The patent systematically modifies key parameters of psychoactive compounds including reducing aromatic ring systems, altering methylation patterns, and changing molecular weight. These parameter changes result in compounds with milder subjective effects while maintaining therapeutic efficacy through different mechanisms, thereby reducing patient reluctance without compromising treatment effectiveness.

The patent develops short-acting compounds that produce subtler, more transient subjective experiences compared to classical psychedelics. These short-living compounds provide sufficient therapeutic benefit during the active window but fade quickly, reducing the intensity and duration of unpleasant subjective effects. This allows patients to experience therapeutic benefits without the overwhelming subjective states that cause reluctance to participate in treatment.

The patent segments the development process into systematic structure-activity relationship (SAR) studies, organizing compound synthesis around modular pharmacological frameworks. By segmenting the molecular design into recognizable pharmacophores and modifying specific functional groups, the patent simplifies the synthesis process and enables more predictable regulatory pathways. This modular approach makes manufacturing more manageable while maintaining treatment effectiveness.

The patent creates a universal framework for synthesizing multiple psychoactive compounds based on common core structures (e.g., compounds of Formula I, II, III, IV sharing common molecular skeletons). This multi-functional approach allows a single synthetic methodology to produce multiple active compounds with different pharmacological profiles, reducing overall manufacturing complexity compared to developing entirely separate compounds. The universal framework also facilitates standardized regulatory submissions across different indications.